378 related articles for article (PubMed ID: 18207123)
1. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
2. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
4. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
5. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
6. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
7. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
9. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
10. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
[TBL] [Abstract][Full Text] [Related]
11. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
12. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
13. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
Hosseini H; Nejabat M; Mehryar M; Yazdchi T; Sedaghat A; Noori F
Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
[TBL] [Abstract][Full Text] [Related]
15. Subconjunctival bevacizumab injection for corneal neovascularization.
Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
Cornea; 2008 Feb; 27(2):142-7. PubMed ID: 18216566
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
[TBL] [Abstract][Full Text] [Related]
17. Subconjunctival bevacizumab for corneal neovascularization.
Doctor PP; Bhat PV; Foster CS
Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits.
Park JH; Joo CK; Chung SK
Cornea; 2015 Apr; 34(4):449-55. PubMed ID: 25651492
[TBL] [Abstract][Full Text] [Related]
19. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
[TBL] [Abstract][Full Text] [Related]
20. Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Yildiz DK; Sener E; Caglar Y
Can J Ophthalmol; 2013 Apr; 48(2):115-20. PubMed ID: 23561605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]